Mirena

Quick links to important sections

Mirena

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirena

What is Mirena? Overview and Quick Facts

Mirena is a unique prescription-only medicine and Long-Acting Reversible Contraceptive (LARC), manufactured by Bayer HealthCare Pharmaceuticals and globally recognized for its high effectiveness as an Intrauterine System (IUS).

Property Description
Active ingredient Levonorgestrel
Form Intrauterine System (IUS) / T-shaped Device
Pharmacological class Progestogens / Hormonal Contraceptives
Common use Long-term contraception, Heavy menstrual bleeding
Origin Synthetic Progestogen (Rx Status)

1. Defining Mirena: A Hormonal Intrauterine System (IUS)

Mirena is a highly reliable LARC that functions as a sophisticated, single-use drug delivery system, classified within the Hormonal Intrauterine System (IUS) category. This device is built upon a T-shaped polyethylene frame designed for intrauterine (local) placement. As the first hormonal IUS to be approved, Mirena maintains a differentiating factor within its class by being approved for the longest continuous use for contraception, up to eight years, a duration clinically recognized for providing effective, long-term protection.

2. Composition and Classification: The Synthetic Progestogen

The system’s single active ingredient is Levonorgestrel, a potent synthetic progestogen chemically derived from 19-nortestosterone. The device contains a total of 52 mg of Levonorgestrel within an elastomer core, ensuring its categorization as a Single-Active-Ingredient Product within the Progestogens pharmacological class. The unique design of the Mirena system, with its specific size and hormone load, is supported by extensive pharmacological studies confirming the consistency of its continuous low-dose release pattern.

3. General Therapeutic Purpose and Delivery Advantage

Mirena's primary therapeutic purpose is to provide long-term reversible contraception, and it is also indicated for reducing heavy menstrual bleeding (menorrhagia) for up to five years in women who choose an IUS. The advantage of this design is the localized delivery system, which concentrates the hormone's action in the uterine cavity while maintaining systemic levels significantly lower than those associated with oral contraceptives. This local action is clinically proven to prevent pregnancy and manage bleeding by promoting endometrial lining thinning.

Regulatory References

  1. Mirena Clinical Review on Levonorgestrel Release

What side effects are possible with Mirena?

Possible side effects and safety information

The safety profile for the Mirena Levonorgestrel-releasing Intrauterine System (IUS) is formally classified by regulatory authorities based on frequency of occurrence, affected organ systems, and specific safety limitations documented in official labeling.

Documented Adverse Reactions and Frequency

Adverse reactions are officially categorized according to their occurrence rate in clinical studies. Very common adverse reactions (occurring in 10% or more of users) include alterations of menstrual bleeding patterns (such as irregular bleeding, spotting, or the absence of periods, known as amenorrhoea), abdominal/pelvic pain, headache, and ovarian cysts. Common reactions (occurring in 1% to less than 10% of users) include depression, nervousness, migraine, nausea, acne, weight increase, breast pain, and IUS expulsion.

These effects are generally classified within the Reproductive System and Breast Disorders, Nervous System Disorders, and Psychiatric Disorders System-Organ Classes.

Serious Safety Considerations

The official labeling highlights several rare but clinically significant adverse reactions. These include risks of Ectopic Pregnancy (pregnancy outside the uterus), serious infections such as Pelvic Inflammatory Disease (PID) (with the highest risk immediately following insertion), and Uterine Perforation (a hole in the uterine wall, most often occurring during insertion), particularly in postpartum or breastfeeding women. Thrombotic events have also been reported in postmarketing experience.

Safety Restrictions and Patterns

The IUS is contraindicated (officially restricted) for use in individuals with known or suspected pregnancy, acute liver disease, liver tumors, uncontrolled pelvic infections, or certain cancers. The frequency of common effects is often time-dependent: menstrual irregularities are more frequent during the first 3 to 6 months after insertion, generally decreasing with continued use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for the Levonorgestrel Intrauterine System (IUS) does not detail specific symptoms of systemic drug overdose. Due to the local, low-dose hormone release, systemic overexposure is officially classified as very unlikely to occur.

Regulators instead focus on life-threatening complications that require immediate emergency action.

Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations: Systemic overdose is officially classified as very unlikely to occur; no specific signs or symptoms are documented in the labeling.
Serious / life-threatening outcomes: Sepsis (including Group A streptococcal sepsis), septic shock, ectopic pregnancy, and septic abortion are documented complications requiring urgent attention.
When immediate medical help is required: Seek immediate medical attention is mandated for symptoms such as unexplained fever, chills, flu-like symptoms, lower abdominal/pelvic pain, unusual bleeding, or odorous discharge.

Overdose Classifications (High-Level)

Classification Official Regulatory Wording
Severity classification: The systemic overdose event is officially classified as very unlikely. Severity focuses on associated, rare but serious complications.
Overdose-context constraints: The local delivery system prevents high systemic exposure, constraining the documented risk to complications inherent to the device's presence.

Resulting Overdose Structure

Official overdose statements:

  • Systemic overdose is officially documented as very unlikely, with no specific symptoms listed for acute levonorgestrel overexposure.
  • Emergency actions mandated by regulators include the removal of the IUS in cases of severe pelvic infection or confirmed intrauterine pregnancy.
  • Immediate medical attention is required for signs of severe infection or ectopic pregnancy, which are the primary help-seeking triggers defined in the labeling.

Connection to the overall overdose profile (3 sentences):

Regulatory documentation defines the overdose profile by stating that systemic overexposure is improbable due to the local hormone release. This regulatory classification shifts the help-seeking mandate to the immediate recognition of life-threatening complications, such as sepsis and ectopic pregnancy. Consequently, the required action is to seek immediate medical attention upon the appearance of specific symptoms, which constitutes the regulator-defined emergency structure for this product.

Therapeutic Uses of Mirena

What Mirena Treats: Main Uses and Benefits

Therapeutic Support

The Mirena IUS addresses key clinical needs by providing long-term hormonal support across three principal therapeutic areas, aligning with its established uses. The system is relevant for sustained, long-acting pregnancy prevention, the management of heavy menstrual bleeding (menorrhagia), and providing endometrial support for patients using systemic estrogen.

For contraception, Mirena is a relevant option for managing symptoms that may interfere with daily functioning, such as the effort related to other daily birth control regimens. The key therapeutic benefit is providing contraceptive support and autonomy, which contributes to a more stable sense of well-being. Regarding heavy bleeding, it is commonly used for conditions characterized by periods of heightened symptoms—specifically, clinically defined menorrhagia and associated severe cramping (dysmenorrhea). The therapeutic benefit generally involves a reduction in blood flow, which helps ease the overall symptom burden and may assist with maintaining functional stability by addressing blood-loss-related fatigue.

Endometrial Support and Quick Fact

Mirena is relevant for providing support to the uterine lining against abnormal overgrowth (hyperplasia) in patients using systemic estrogen. This is applied in scenarios where additional management of discomfort is required, supporting the patient during difficult episodes and contributing to easing discomfort associated with combined hormone use.

Quick Fact: Symptomatic Management for Heightened Menstrual Flow and Pronounced Cramping

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mirena — Official Regulatory Information

Category Eligibility Status (Strictly Regulatory Wording)
Populations for whom use is allowed Women of reproductive age (for contraception). Postmenopausal women using systemic estrogen (for endometrial support).
Populations for whom use is contraindicated Known or suspected pregnancy; Acute liver disease or tumor; Known or suspected breast cancer or other progestin-sensitive cancer (now or in the past); Acute pelvic inflammatory disease (PID) or a history of PID (unless subsequent intrauterine pregnancy); Uterine or cervical malignancy; Undiagnosed abnormal genital bleeding; Congenital or acquired uterine anomaly if it distorts the uterine cavity.
Age-related eligibility rules Use is not indicated before menarche. The product has not been studied in women over the age of 65 years.
Condition-specific eligibility rules Mirena has not been studied in women with renal impairment. It is contraindicated in acute liver disease. Blood glucose concentration should be monitored in diabetic users.
Pregnancy and lactation eligibility status Contraindicated in known or suspected pregnancy. The risk of uterine perforation is increased in women who are breastfeeding at the time of insertion.

Connection to the overall eligibility profile

Regulatory documents establish the eligible population as women of reproductive age while defining strict contraindications based on disease status, anatomical integrity, and physiological state. Eligibility classifications also include groups requiring caution (e.g., those with coagulopathy) and groups where use is not established due to limited clinical data (e.g., renal impairment) in official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Mirena is based on documented pharmacokinetic effects on the active ingredient, levonorgestrel, and specific procedural constraints.

Interacting Substance Category Official Regulatory Statement
Enzyme-Inducing Substances (CYP3A4) Substances that induce CYP3A4, such as Phenytoin, Carbamazepine, and Rifampicin, may decrease the serum concentration of the progestin. Herbal products, including St. John's wort, are also documented as enzyme inducers.
Enzyme-Inhibiting Substances (CYP3A4) Strong and moderate CYP3A4 inhibitors, such as Azole Antifungals and Macrolides, are documented to increase the plasma concentration of levonorgestrel.
Formal Restrictions Co-administration with Mifepristone is subject to a mandatory procedural constraint. The Mirena IUS must be removed before treatment with Mifepristone begins for the purpose of pregnancy termination.
Food & Beverage Grapefruit juice is officially documented as a moderate CYP3A4 inhibitor that can increase the plasma concentrations of levonorgestrel.

Connection to the overall interaction profile:

Regulatory documentation formalizes the theoretical pharmacokinetic interaction pattern where enzyme inducers and inhibitors can cause documented changes in progestin serum levels. The profile also clearly establishes a non-negotiable procedural requirement for the use of the IUS with Mifepristone. No mandatory time separation rules or population-specific interaction considerations are formally documented in the regulatory label.

Mechanism of Action

The mechanism of the Levonorgestrel-releasing Intrauterine System involves multi-layered actions driven by the local release of the synthetic hormone directly into the reproductive tract.


Local Progesterone Receptor Agonism

This domain covers the molecular interaction with the progesterone receptor ( PR) and the resulting tissue-level cascade. The device continuously releases Levonorgestrel, a progestogen agonist, which saturates the PRs within the uterine lining (endometrium). This interaction initiates a signaling sequence that suppresses cell proliferation and growth, resulting in a non-proliferative, atrophic state in the lining.


Cervical Barrier and Sperm Function Modulation

This domain addresses the physical and functional changes induced by the hormone in the lower reproductive tract. Levonorgestrel modulates the cervical glands, causing the cervical mucus to thicken and become dense and viscous. This physiological change creates a physical barrier that restricts sperm passage. Additionally, the hormone directly interferes with sperm motility and capacitation within the uterine environment, resulting in a reduction of gamete function.


Secondary HPO Axis Modulation

This domain concerns the low-level systemic effect of the hormone on the central reproductive pathway. Although the primary action is local, a small amount of Levonorgestrel is absorbed systemically, which can partially blunt the LH surge and thus inhibit ovulation in some users. This modulation of the Hypothalamic-Pituitary-Ovarian ( HPO) axis is considered a secondary mechanistic component, as the system's primary mechanism is independent of consistent anovulation.

Dosage and Administration Information

Official Administration Guidelines for Mirena

Mirena is administered as a single Intrauterine System (IUS), a T-shaped device placed directly into the uterine cavity. This method constitutes a local, intrauterine route of administration that requires placement by a trained healthcare professional using strict aseptic technique.


Dosing Pattern and Frequency

The IUS is a fixed-dose system that delivers a continuous, low-dose regimen of its active ingredient, levonorgestrel. The device contains a total of 52 mg of levonorgestrel and initiates hormone release at an approximate rate of 20 micrograms (mcg) per 24 hours. Unlike daily or cyclic oral medications, this system requires no further action or scheduling from the patient once inserted, as the dose is released steadily over years.


Contextual Instructions and Duration

For proper placement, insertion is generally scheduled within seven days of the start of menstruation. If the device is inserted outside of this window, specific instructions must be followed, including the temporary use of back-up contraception. For postpartum individuals, insertion must be delayed until the uterus has fully involuted, typically no sooner than six weeks after delivery. Mirena is officially approved for use in postpubertal females.

The IUS must be removed or replaced based on the specific approved duration for its use. When used for contraception, the maximum approved duration is 8 years. When used for heavy menstrual bleeding, the maximum approved duration is 5 years. Once the approved term is complete, the system must be removed or replaced by a healthcare professional to maintain its defined use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mirena


Evidence for Long-Term Reversible Contraception

Research examining the use of the intrauterine system (IUS) for long-term pregnancy prevention has relied on two main types of studies: large Randomized Controlled Trials (RCTs) and extensive observational cohort studies. These studies were used in research exploring how long the system was studied for pregnancy prevention and what the observed continuation rates were over time. The populations studied included women of reproductive age who required long-acting birth control, encompassing both women who had previously given birth and those who had not.

Findings described patterns observed in the studies, where researchers consistently reported measurements of the Pearl Index (a standard measure of the rate of unintended pregnancies). Data show patterns related to how long women continued using the IUS, tracking measurements during the approved use duration. The evidence base for the initial five years includes a high volume of data from large studies, but the research exploring measurements beyond the maximum approved duration remains limited, and follow-up is ongoing in this area.


Evidence for Heavy Menstrual Bleeding Management

The IUS was studied for its use in managing conditions characterized by periods of heightened symptoms, specifically heavy menstrual bleeding (menorrhagia). Research used Randomized Controlled Trials (RCTs) and high-quality clinical trials to compare the IUS against oral medications and other treatments. The outcomes monitored were quantifiable axes of change, including Menstrual Blood Loss (MBL), measured using standardized clinical methods, and tracking of blood counts, such as Hemoglobin and Ferritin levels.

Studies reported measurements describing how MBL volumes evolved during the study period, typically over six months to one year, with follow-up tracked up to five years. Evidence contributes to understanding symptom patterns and how systemic markers evolved in the observed populations. Comparative evidence is lacking for specific non-IUS surgical alternatives. Additionally, data focusing on severe or complex causes of heavy bleeding remain limited.


Key Research Gaps and Uncertainties

The evidence landscape provides substantial context, yet certain areas remain insufficiently studied. For instance, changes in dysmenorrhea (painful periods) were observed in some studies as a secondary effect, but dedicated, large-scale RCTs focused on pelvic pain as the primary measurement are rare. Therefore, certainty remains low regarding the isolated evidence for this specific measurement. The evidence quality varies across studies, and comparative evidence against all emerging long-acting contraceptive and menorrhagia treatments is continually developing.

Frequently Asked Questions (FAQ)

Common questions about Mirena (FAQ)


Q: What is the effectiveness rate of Mirena for preventing pregnancy?

Official information from clinical trials indicates that Mirena offers highly effective pregnancy protection. Its efficacy is described using the Pearl Index, which reflects a low rate of unintended pregnancy. Because the system does not rely on daily user compliance, its effectiveness is considered consistent across both typical and perfect use.


Q: How quickly does Mirena start to prevent pregnancy after insertion?

According to official product information, if the device is inserted during the first seven days of the menstrual cycle, backup contraception is not specified as needed in the product information. If it is inserted outside of this timeframe, a barrier method should be used, or the patient should abstain from intercourse for seven days.


Q: Are there any specific safety concerns for women who are breastfeeding and using Mirena?

Regulatory documents state that the risk of uterine perforation is increased in women who are breastfeeding at the time of insertion, particularly soon after delivery. While a small amount of the hormone levonorgestrel is detected in breast milk, studies have reported no effects on infant growth and development measures up to 12 months.


Q: What should a patient do if they can no longer feel the Mirena threads?

The official information advises contacting a healthcare provider if the threads cannot be felt. The inability to feel the threads may be a sign that the system has been expelled from the uterus or that the threads have retracted, which requires professional evaluation.


Q: What is the recommended timeframe for Mirena removal if it is used only for heavy menstrual bleeding?

Mirena is approved for use up to five years when the primary indication is the treatment of heavy menstrual bleeding. After the end of the fifth year, the device must be removed by a healthcare professional, even if the patient is not seeking replacement.


Q: Does Mirena interfere with common over-the-counter pain medications like ibuprofen?

Official drug interaction summaries do not list common over-the-counter pain relievers, such as ibuprofen or acetaminophen, as substances that significantly affect the systemic hormone concentration or the effectiveness of Mirena. The primary warnings involve specific medications that affect liver enzymes.


Q: Do antibiotics or herbal supplements affect the effectiveness of Mirena?

Official documents list some substances that affect liver enzymes (CYP3A4 inducers/inhibitors) that may potentially change levonorgestrel blood levels. The herbal product St. John’s wort is specifically named as an enzyme inducer. While some antibiotics are listed as enzyme inhibitors, the IUS primarily acts locally, and official documentation does not indicate a widespread loss of effectiveness from common antibiotics.


Q: Can Mirena be used by women who have never had children (nulliparous patients)?

Yes, official prescribing information confirms that Mirena may be used for contraception in women of reproductive age whether they have previously given birth or not.


Q: What kind of changes to the menstrual period are commonly reported with Mirena?

Changes in menstrual bleeding patterns are listed as a very common reaction, especially during the first three to six months after insertion. These changes can include irregular bleeding, spotting, shorter or lighter periods, or the complete absence of periods (amenorrhoea). Official information describes these changes as common expectations with continued use.


Q: Is it typical for periods to stop completely while using Mirena?

The absence of menstrual periods, medically known as amenorrhoea, is listed as a very common side effect in official documentation. Clinical data indicates that this occurs in approximately 2 out of 10 women after one year of Mirena use.


Q: Can a sexual partner feel the threads of the device during intercourse?

Official patient information states that Mirena should not interfere with sexual intercourse. While the threads are present in the vagina for self-checking and removal, if a sexual partner can feel them, a healthcare professional may be able to trim them shorter.


Q: How long after Mirena removal can a patient expect to become pregnant?

The device is a reversible form of contraception. Clinical data indicates that approximately 8 out of 10 women who seek pregnancy conceive within the first 12 months after Mirena is removed, showing that the system does not alter the course of future fertility.


Q: What are the main differences between Mirena and other hormonal IUDs like Kyleena or Skyla?

The main differences among the hormonal intrauterine systems are generally based on the total levonorgestrel hormone dose, the daily release rate, and the approved duration of use. Mirena has a higher initial hormone load and is approved for up to eight years for contraception, which is the longest duration in its class.


Q: What happens if Mirena is not removed after its approved duration of use?

Once the approved duration of use (8 years for contraception or 5 years for heavy bleeding) has passed, the device must be removed or replaced by a professional to maintain its defined use. Using the system beyond the approved duration may result in a loss of contraceptive efficacy.


Q: Does Mirena protect against sexually transmitted infections (STIs)?

Official safety information clearly states that Mirena does not provide any protection against Human Immunodeficiency Virus (HIV/AIDS) or any other sexually transmitted infections (STIs).


Q: Can a patient use tampons or menstrual cups with the Mirena device in place?

Yes, official patient information confirms that because Mirena is placed in the uterus, not the vagina, patients can continue to use tampons or menstrual cups with the device in place.


Q: What is the typical follow-up schedule recommended after the device is inserted?

Official documentation states that a healthcare provider should check the intrauterine system after a few weeks (typically 4 to 6 weeks) following insertion to confirm it is correctly positioned. After this initial check-up, routine annual check-ups are recommended.


Q: Are there specific symptoms that warrant immediate medical attention after Mirena insertion?

Official warnings describe certain symptoms that warrant contacting a healthcare provider, such as signs of infection (fever, chills, unusual discharge), severe or worsening lower abdominal/pelvic pain, or symptoms suggestive of an ectopic pregnancy.


Q: Does the efficacy of Mirena change over its years of use?

Clinical trials show that the contraceptive efficacy remains high throughout the full approved duration of use. While the hormone release rate does decline progressively, the low failure rate remains reliable, even in the final years of the approved duration.


Q: Is Mirena insertion painful, and is pain relief typically discussed or available?

Official documentation notes that the insertion procedure can be associated with some pain and/or bleeding, as well as vasovagal reactions (a drop in heart rate and blood pressure). Healthcare professionals may discuss pain management options, including the administration of analgesics (pain relievers), prior to the insertion procedure.


Q: Can Mirena be used as an emergency contraceptive (EC)?

Official safety information clearly states that Mirena cannot be used as an emergency contraceptive (EC).


Q: Is it normal to experience mild cramping on and off after the initial insertion period?

Abdominal or pelvic pain, including cramping, is listed as a very common adverse reaction in official documents. Patients should be aware of accompanying symptoms; severe, persistent cramping or cramping accompanied by fever or heavy bleeding are listed as reasons to seek professional guidance.


Q: Does Mirena interfere with procedures like MRI scans or other medical imaging?

Published data indicates that Mirena is generally considered safe and compatible with Magnetic Resonance Imaging (MRI) systems, even high-field systems. The device should not cause significant interference or pose a risk during the scan.


Q: Can the hormones from Mirena cause mood changes or affect mental health?

Official documentation lists certain effects classified under Psychiatric Disorders that were reported in clinical trials. Specifically, depression and nervousness are listed as common adverse reactions.

How should Mirena be stored and disposed of?

Official Storage and Disposal Guidelines

Storage of the Mirena intrauterine system must adhere strictly to the conditions specified in regulatory labeling. The system must be stored in its original, unopened package at room temperature, typically between 15 C and 30 C. It is mandatory to protect the package from moisture and direct sunlight to maintain product stability and sterility. For safety, the product must be kept out of the sight and reach of children and pets.

Since Mirena is a sterile, single-use device, it must not be re-sterilized. Before use, the expiration date on the label must be checked. Any unused or expired product must be disposed of in accordance with local regulatory requirements. Once a Mirena system has been used, it is officially classified and should be handled as biohazardous waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirena found in:

A-Z Index: